Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.73 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.73 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.73 |
| ▸ | CDK1 | P06493 | 5/20 | 0.58 |
| ▸ | CDK4 | P11802 | 5/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.58 |
| ▸ | CCND1 | P24385 | 4/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CDK7 | P50613 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | CCNH | P51946 | 1/20 | 0.58 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112900 | 0.88 | CDK2 (0.57) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL21359488 | 0.86 | CDK2 (0.55) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL27574298 | 0.84 | CDK2 (0.71) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL24624620 | 0.84 | CDK2 (0.71) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL2463824 | 0.84 | CDK2 (1.00) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL16138426 | 0.83 | CDK2 (0.53) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL13436494 | 0.83 | CDK2 (0.69) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL5835525 | 0.83 | CDK2 (0.71) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL17244883 | 0.82 | CDK2 (0.63) | CDK2CCNE1CDK5CDK1CDK4 | |
| SCHEMBL13436511 | 0.81 | CDK2 (0.67) | CDK2CCNE1CDK5CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-10675286-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9790228-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC | 2016-06-16 | — | — | US | disclosed |
| US-9296742-B2 | Heterocyclic kinase inhibitors | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-7491737-B2 | Heterarylpiperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| CN-100410245-C | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2008-08-13 | — | — | CN | disclosed |
| CN-1425009-A | Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675286-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CDK2 100/4885CCNE1 1333/4885CDK5 83/4885 |
| US-20160168157-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | CDK2 28/4885CCNE1 440/4885CDK5 78/4885 |
| US-20140206685-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | CDK2 28/4885CCNE1 440/4885CDK5 78/4885 |
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | CDK2 77/4885CCNE1 425/4885CDK5 160/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CDK2 40/4885CCNE1 91/4885CDK5 142/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CDK2 130/4885CCNE1 339/4885CDK5 471/4885 |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | CDK2 18/4885CCNE1 8/4885CDK5 127/4885 |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | CDK2 293/4885CCNE1 1432/4885CDK5 364/4885 |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | CDK2 34/4885CCNE1 214/4885CDK5 322/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | CDK2 28/4885CCNE1 440/4885CDK5 78/4885 |
| US-20180055852-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CDK2 100/4885CCNE1 1333/4885CDK5 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.